Objective: Intravenous labetalol and hydralazine are both considered first-line medications for the management of acute-onset, severe hypertension in pregnant and postpartum women. The study compared the efficacy and ...Objective: Intravenous labetalol and hydralazine are both considered first-line medications for the management of acute-onset, severe hypertension in pregnant and postpartum women. The study compared the efficacy and safety profile of intravenous labetalol and hydralazine in the control hypertension in severe pre-eclampsia. Materials and Methods: One hundred patients who presented with severe pre-eclampsia were randomized into two study groups. The fifty patients in each arm of the study received either intravenous labetalol or intravenous hydralazine for the control of blood pressure. Results: The mean age of the labetalol subjects was 28.6 ± 5.47 years while that of their hydralazine counterparts was 29.12 ± 5.77 years. The majority of respondents in both groups were primigravidae (76% vs. 78%) (P = 0.813). The number of doses of drug needed to significantly lower the mean systolic blood pressure was slightly lower in the labetalol group (2 doses) compared to the hydralazine group (5 doses) (t = 0.803<sup>Y</sup>, P = 0.977). The incidence of headaches which were the commonest complaints was comparable in both groups 8% and 10% of respondents respectively (P > 0.05). Conclusion: Although both intravenous labetalol and hydralazine are useful in patients with severe pre-eclampsia, the response to labetalol was better with comparable side effects.展开更多
文摘Objective: Intravenous labetalol and hydralazine are both considered first-line medications for the management of acute-onset, severe hypertension in pregnant and postpartum women. The study compared the efficacy and safety profile of intravenous labetalol and hydralazine in the control hypertension in severe pre-eclampsia. Materials and Methods: One hundred patients who presented with severe pre-eclampsia were randomized into two study groups. The fifty patients in each arm of the study received either intravenous labetalol or intravenous hydralazine for the control of blood pressure. Results: The mean age of the labetalol subjects was 28.6 ± 5.47 years while that of their hydralazine counterparts was 29.12 ± 5.77 years. The majority of respondents in both groups were primigravidae (76% vs. 78%) (P = 0.813). The number of doses of drug needed to significantly lower the mean systolic blood pressure was slightly lower in the labetalol group (2 doses) compared to the hydralazine group (5 doses) (t = 0.803<sup>Y</sup>, P = 0.977). The incidence of headaches which were the commonest complaints was comparable in both groups 8% and 10% of respondents respectively (P > 0.05). Conclusion: Although both intravenous labetalol and hydralazine are useful in patients with severe pre-eclampsia, the response to labetalol was better with comparable side effects.
文摘目的:通过不同类型的重度子前期(severe preeclampsia,S-PE)早产和自发早产的对比分析,探讨影响S-PE早产结局的相关因素。方法:将重度子前期(研究组)早产72例(早产儿83例),按不同孕周分为早期早产、中型早产及轻型早产3类,分别与相同类型的自发早产(对照组)222例(早产儿279例)进行孕产妇及围生儿结局对比分析。结果:研究组及对照组3类型间的早产儿病死率差异有显著性(P=0.000)。研究组与对照组同类型间早产儿病死率比较,差异无显著性(P>0.05);研究组早期早产儿平均出生体重明显低于对照组(P=0.003),而早产儿并发症发生率与对照组比较,差异无显著性(P>0.05);研究组中的中型早产新生儿除重度窒息明显高于对照组外(P=0.022),新生儿平均出生体重、新生儿轻度窒息率、新生儿病死率及新生儿加强护理NICU(neonatel intensive care unit,NICU)住院日和住院费两组间差异无显著性;在轻型早产组,除研究组NICU住院日明显长于对照组外(P=0.000),两组间其他观察指标的差异均无显著性。多元回归分析显示,早产的分娩孕龄是影响重度子前期早产儿死亡的主要因素;促胎肺成熟和孕期检查是影响新生儿病率的主要因素。结论:不论重度子前期早产还是自发早产,在早期早产阶段影响围生儿预后的主要因素是分娩孕龄,重度子前期早产与自发早产围生结局无明显差异。
